Specific bcr-abl-directed antisense nucleic acids and ribozymes: a tool for the treatment of chronic myelogenous leukemia?

Recent Results Cancer Res. 1998:144:127-38. doi: 10.1007/978-3-642-46836-0_14.
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Mice
  • Oligonucleotides, Antisense / therapeutic use*
  • RNA, Catalytic / therapeutic use*
  • RNA, Complementary / analysis

Substances

  • Oligonucleotides, Antisense
  • RNA, Catalytic
  • RNA, Complementary
  • Fusion Proteins, bcr-abl